In spite of current improvement of clinical outcome offered by antibody-based targeted therapies, such as VEGF targeted therapies, ccRCC still suffers from high cancer-related deaths annually, which requires more powerful strategies to improve patient survival outcomes. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.